

Ken-ichi Inui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7767202/publications.pdf>

Version: 2024-02-01

154
papers

11,876
citations

18436

62
h-index

29081

104
g-index

155
all docs

155
docs citations

155
times ranked

7749
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. European Journal of Pharmaceutical Sciences, 2021, 158, 105666.	1.9	3
2	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. British Journal of Pharmacology, 2021, 178, S412-S513.	2.7	114
3	Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Scientific Reports, 2016, 6, 27557.	1.6	20
4	Telaprevir-Induced Renal Adverse Events in Japanese Patients Reported in the PMDA Adverse Drug Reactions Reporting Database. Therapeutic Innovation and Regulatory Science, 2016, 50, 355-360.	0.8	2
5	Pharmacological and Toxicological Significance of the Organic Cation Transporters OCT and MATE: Drug Disposition, Interaction and Toxicity. , 2016, , 73-92.		2
6	Valacyclovir-Induced Acute Kidney Injury in Japanese Patients Based on the PMDA Adverse Drug Reactions Reporting Database. Therapeutic Innovation and Regulatory Science, 2015, 49, 81-85.	0.8	5
7	Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. , 2015, 152, 125-134.		67
8	Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury. Cancer Chemotherapy and Pharmacology, 2015, 75, 1191-1197.	1.1	8
9	Evaluation of the Potency of Telaprevir and Its Metabolites as Inhibitors of Renal Organic Cation Transporters, a Potential Mechanism for the Elevation of Serum Creatinine. Drug Metabolism and Pharmacokinetics, 2014, 29, 266-271.	1.1	7
10	Developmental trajectory of intestinal <scp>MDR1/ABCB1</scp> mRNA expression in children. British Journal of Clinical Pharmacology, 2014, 77, 910-912.	1.1	19
11	The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma. Therapeutic Drug Monitoring, 2014, 36, 310-316.	1.0	35
12	Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins. Pharmaceutical Research, 2014, 31, 136-147.	1.7	51
13	Association between CYP3A5 Genotypes in Graft Liver and Increase in Tacrolimus Biotransformation from Steroid Treatment in Living-donor Liver Transplant Patients. Drug Metabolism and Pharmacokinetics, 2014, 29, 83-89.	1.1	19
14	Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clinical Pharmacokinetics, 2013, 52, 593-609.	1.6	77
15	Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Molecular Aspects of Medicine, 2013, 34, 661-668.	2.7	78
16	Novel riboflavin transporter family RFVT/SLC52: Identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Molecular Aspects of Medicine, 2013, 34, 693-701.	2.7	125
17	Urinary chemokine (C-C motif) ligand 2 (monocyte chemoattractant protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. Biochemical Pharmacology, 2013, 85, 570-582.	2.0	30
18	Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney. AAPS Journal, 2013, 15, 581-588.	2.2	162

#	ARTICLE	IF	CITATIONS
19	Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3302-3308.	1.6	56
20	Developmental expression of renal organic anion transporters in rat kidney and its effect on renal secretion of phenolsulfonphthalein. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, F1640-F1649.	1.3	18
21	Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 631-639.	1.1	82
22	Renal Tubular Secretion of Varenicline by Multidrug and Toxin Extrusion (MATE) Transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 563-569.	1.1	15
23	Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. <i>European Journal of Pharmacology</i> , 2012, 696, 143-154.	1.7	61
24	Recent Advances in Structural Biology of Peptide Transporters. <i>Current Topics in Membranes</i> , 2012, 70, 257-274.	0.5	39
25	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 259-266.	0.8	17
26	Renal Excretion of Vancomycin in Rats with Acute Renal Failure. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 154-157.	1.2	8
27	Tacrolimus Therapy as an Alternative to Thiopurines for Maintaining Remission in Patients With Refractory Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 526-530.	1.1	41
28	Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. <i>British Journal of Pharmacology</i> , 2011, 164, 1817-1825.	2.7	155
29	Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non-Small-Cell Lung Cancer With Pleural Effusion. <i>Clinical Lung Cancer</i> , 2011, 12, 307-312.	1.1	21
30	Organic cation transporter OCT/SLC22A and H ⁺ /organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. <i>Biochemical Pharmacology</i> , 2011, 81, 563-568.	2.0	148
31	Human NPC1L1 Expression is Positively Regulated by PPAR α . <i>Pharmaceutical Research</i> , 2011, 28, 405-412.	1.7	33
32	Effects of Metabolic Acidosis on Expression Levels of Renal Drug Transporters. <i>Pharmaceutical Research</i> , 2011, 28, 1023-1030.	1.7	18
33	Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. <i>Human Mutation</i> , 2011, 32, E1976-E1984.	1.1	96
34	Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 135-138.	0.7	48
35	Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 950-955.	0.5	125
36	A Case of Radiation Recall Pneumonitis Induced by Erlotinib, Which Can be Related to High Plasma Concentration. <i>Journal of Thoracic Oncology</i> , 2010, 5, 924-925.	0.5	30

#	ARTICLE	IF	CITATIONS
37	The Globalization of JSSX DMPK Progress in Research. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 319.	1.1	0
38	A Transient Increase of Calcineurin Phosphatase Activity in Living-Donor Kidney Transplant Recipients with Acute Rejection. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 411-417.	1.1	19
39	Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 601-605.	0.5	47
40	Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. <i>International Journal of Clinical Oncology</i> , 2010, 15, 512-514.	1.0	22
41	Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. <i>BMC Medicine</i> , 2010, 8, 76.	2.3	96
42	mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. <i>Biochemical Pharmacology</i> , 2010, 79, 67-76.	2.0	25
43	Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. <i>Biochemical Pharmacology</i> , 2010, 80, 1762-1767.	2.0	180
44	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 886-891.	1.4	25
45	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. <i>Annals of Oncology</i> , 2010, 21, 1382-1383.	0.6	51
46	Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray. <i>Journal of Biochemistry</i> , 2010, 148, 557-563.	0.9	2
47	Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 651-656.	1.3	49
48	Identification and Comparative Functional Characterization of a New Human Riboflavin Transporter hRFT3 Expressed in the Brain. <i>Journal of Nutrition</i> , 2010, 140, 1220-1226.	1.3	121
49	Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F923-F934.	1.3	12
50	Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 190-199.	1.1	66
51	Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients. <i>Drug Metabolism and Disposition</i> , 2009, 37, 821-826.	1.7	38
52	Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 185-191.	1.3	170
53	Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. <i>Journal of Human Genetics</i> , 2009, 54, 40-46.	1.1	79
54	Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin. <i>Molecular Pharmacology</i> , 2009, 75, 1280-1286.	1.0	162

#	ARTICLE	IF	CITATIONS
55	Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. <i>Biochemical Pharmacology</i> , 2009, 77, 1429-1436.	2.0	48
56	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. <i>Biochemical Pharmacology</i> , 2009, 78, 1263-1271.	2.0	79
57	UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. <i>International Journal of Clinical Oncology</i> , 2009, 14, 136-142.	1.0	90
58	MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients. <i>Pharmaceutical Research</i> , 2009, 26, 1590-1595.	1.7	18
59	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 647-656.	0.7	20
60	A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 99-104.	0.6	21
61	Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. <i>Journal of Human Genetics</i> , 2008, 53, 607-614.	1.1	42
62	Physiological and pharmacokinetic roles of H ⁺ /organic cation antiporters (MATE/SLC47A). <i>Biochemical Pharmacology</i> , 2008, 75, 1689-1696.	2.0	131
63	Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. <i>Biochemical Pharmacology</i> , 2008, 76, 894-903.	2.0	86
64	Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 610-616.	1.3	16
65	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F247-F252.	1.3	34
66	Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 313-317.	1.1	15
67	Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 469-475.	1.1	11
68	Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. <i>American Journal of Physiology - Cell Physiology</i> , 2008, 295, C632-C641.	2.1	126
69	Altered Pharmacokinetics of Cationic Drugs Caused by Down-Regulation of Renal Rat Organic Cation Transporter 2 (<i>Slc22a2</i>) and Rat Multidrug and Toxin Extrusion 1 (<i>Slc47a1</i>) in Ischemia/Reperfusion-Induced Acute Kidney Injury. <i>Drug Metabolism and Disposition</i> , 2008, 36, 649-654.	1.7	57
70	Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 134-138.	1.1	29
71	Identification of Essential Histidine and Cysteine Residues of the H ⁺ /Organic Cation Antiporter Multidrug and Toxin Extrusion (MATE). <i>Molecular Pharmacology</i> , 2007, 71, 1487-1493.	1.0	33
72	Critical roles of Sp1 in gene expression of human and rat H ⁺ /organic cation antiporter MATE1. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1564-F1570.	1.3	38

#	ARTICLE	IF	CITATIONS
73	Cl ⁻ -dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F391-F397.	1.3	8
74	A Novel Approach to Therapeutic Angiogenesis for Patients With Critical Limb Ischemia by Sustained Release of Basic Fibroblast Growth Factor Using Biodegradable Gelatin Hydrogel An Initial Report of the Phase I-IIa Study. <i>Circulation Journal</i> , 2007, 71, 1181-1186.	0.7	121
75	Oppositely directed H ⁺ gradient functions as a driving force of rat H ⁺ /organic cation antiporter MATE1. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F593-F598.	1.3	72
76	Gene expression and regulation of drug transporters in the intestine and kidney. <i>Biochemical Pharmacology</i> , 2007, 73, 440-449.	2.0	83
77	Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. <i>Biochemical Pharmacology</i> , 2007, 73, 1482-1490.	2.0	44
78	Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. <i>Biochemical Pharmacology</i> , 2007, 74, 477-487.	2.0	217
79	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H ⁺ -organic cation antiporters. <i>Biochemical Pharmacology</i> , 2007, 74, 359-371.	2.0	369
80	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 119-127.	0.7	125
81	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 90-102.	2.3	50
82	Molecular Cloning, Functional Characterization and Tissue Distribution of Rat H ⁺ /Organic Cation Antiporter MATE1. <i>Pharmaceutical Research</i> , 2006, 23, 1696-1701.	1.7	120
83	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
84	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing. <i>Liver Transplantation</i> , 2006, 12, 292-300.	1.3	22
85	Interactions of Fluoroquinolone Antibacterials, DX-619 and Levofloxacin, with Creatinine Transport by Renal Organic Cation Transporter hOCT2. <i>Drug Metabolism and Pharmacokinetics</i> , 2006, 21, 432-436.	1.1	24
86	Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1 and Multidrug and Toxin Extrusion Family). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 879-886.	1.3	300
87	Identification and Functional Characterization of a New Human Kidney-Specific H ⁺ /Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2127-2135.	3.0	348
88	Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypertensive Drug Midodrine, and Its Amino Acid Derivatives. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 455-460.	1.3	62
89	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 168-181.	2.3	75
90	Computational modelling of H ⁺ -coupled peptide transport via human PEPT1. <i>Journal of Physiology</i> , 2005, 565, 429-439.	1.3	30

#	ARTICLE	IF	CITATIONS
91	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. <i>Biochemical Pharmacology</i> , 2005, 70, 1104-1113.	2.0	114
92	Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. <i>Biochemical Pharmacology</i> , 2005, 70, 1823-1831.	2.0	152
93	Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. <i>Biochemical Pharmacology</i> , 2005, 70, 1756-1763.	2.0	78
94	Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2. <i>Pharmaceutical Research</i> , 2005, 22, 255-259.	1.7	156
95	Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis. <i>Pharmaceutical Research</i> , 2005, 22, 2016-2022.	1.7	35
96	Metformin is a Superior Substrate for Renal Organic Cation Transporter OCT2 rather than Hepatic OCT1. <i>Drug Metabolism and Pharmacokinetics</i> , 2005, 20, 379-386.	1.1	313
97	Distinct Inhibitory Effects of Tacrolimus and Cyclosporin A on Calcineurin Phosphatase Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 816-825.	1.3	38
98	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 3569-3574.	3.3	261
99	Lansoprazole-Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism. <i>Annals of Pharmacotherapy</i> , 2004, 38, 791-794.	0.9	36
100	Methotrexate-Loxoprofen Interaction: Involvement of Human Organic Anion Transporters hOAT1 and hOAT3. <i>Drug Metabolism and Pharmacokinetics</i> , 2004, 19, 369-374.	1.1	86
101	Gene expression variance based on random sequencing in rat remnant kidney. <i>Kidney International</i> , 2004, 66, 29-45.	2.6	15
102	Expression Levels of Renal Organic Anion Transporters (OATs) and Their Correlation with Anionic Drug Excretion in Patients with Renal Diseases. <i>Pharmaceutical Research</i> , 2004, 21, 61-67.	1.7	95
103	Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney. <i>Pharmaceutical Research</i> , 2004, 21, 976-981.	1.7	180
104	Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. <i>Journal of Human Genetics</i> , 2004, 49, 40-45.	1.1	28
105	Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 416-420.	1.0	44
106	(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Peptide Transporters: Structure, Function, Regulation and Application for Drug Delivery. <i>Current Drug Metabolism</i> , 2004, 5, 85-94.	0.7	167
107	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 471-478.	5.7	182
108	Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1161-1178.	1.6	38

#	ARTICLE	IF	CITATIONS
109	Distinct transport activity of tetraethylammonium from l-carnitine in rat renal brush-border membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1609, 218-224.	1.4	7
110	cDNA Cloning, Functional Characterization, and Tissue Distribution of an Alternatively Spliced Variant of Organic Cation Transporter hOCT2 Predominantly Expressed in the Human Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1703-1710.	3.0	114
111	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 451-457.	5.7	186
112	Rat Renal Organic Anion Transporter rOAT1 Mediates Transport of Urinary-Excreted Cephalosporins, but not of Biliary-Excreted Cefoperazone. <i>Drug Metabolism and Pharmacokinetics</i> , 2002, 17, 125-129.	1.1	23
113	Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. <i>Kidney International</i> , 2002, 62, 514-524.	2.6	132
114	Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 866-874.	3.0	450
115	Interaction of Azole Antifungal Agents with Human P-glycoprotein Expressed in a Kidney Epithelial Cell Line, LLC-PK1.. <i>Drug Metabolism and Pharmacokinetics</i> , 2001, 16, 5-11.	0.0	1
116	Independent organic cation transport activity of Na ⁺ -l-carnitine cotransport system in LLC-PK ₁ cells. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F273-F279.	1.3	4
117	Upregulation of H ⁺ -peptide cotransporter PEPT2 in rat remnant kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F1109-F1116.	1.3	39
118	Distinct transport characteristics of basolateral peptide transporters between MDCK and Caco-2 cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2001, 443, 31-37.	1.3	15
119	Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. <i>Kidney International</i> , 2001, 60, 1058-1068.	2.6	40
120	Effects of tacrolimus and cyclosporin A on peptide transporter PEPT1 in Caco-2 cells. <i>Pharmaceutical Research</i> , 2001, 18, 713-717.	1.7	7
121	Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 308-316.	2.3	120
122	Cellular and molecular aspects of drug transport in the kidney. <i>Kidney International</i> , 2000, 58, 944-958.	2.6	404
123	Kinetic analysis of p-aminohippurate transport in the OK kidney epithelial cell line. <i>Pharmaceutical Research</i> , 2000, 17, 1155-1157.	1.7	4
124	Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. <i>Histochemistry and Cell Biology</i> , 2000, 114, 175-180.	0.8	74
125	Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. <i>Pflugers Archiv European Journal of Physiology</i> , 2000, 440, 679-684.	1.3	91
126	Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G563-G569.	1.6	29

#	ARTICLE	IF	CITATIONS
127	Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. <i>FEBS Letters</i> , 2000, 473, 173-176.	1.3	125
128	Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. <i>British Journal of Pharmacology</i> , 1999, 128, 1159-1164.	2.7	29
129	Peptide transporter in the rat small intestine: ultrastructural localization and the effect of starvation and administration of amino acids. <i>The Histochemical Journal</i> , 1999, 31, 169-174.	0.6	103
130	Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. <i>Pharmaceutical Research</i> , 1999, 16, 534-539.	1.7	37
131	Effects of arbekacin and vancomycin on release of lactate dehydrogenase and fragmentation of DNA in LLC-PK1 kidney epithelial cells. <i>Pharmaceutical Research</i> , 1999, 16, 1132-1135.	1.7	3
132	Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. <i>FEBS Letters</i> , 1999, 459, 128-132.	1.3	38
133	Gender differences in expression of organic cation transporter OCT2 in rat kidney. <i>FEBS Letters</i> , 1999, 461, 339-342.	1.3	148
134	Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport. <i>Toxicology Letters</i> , 1999, 106, 229-235.	0.4	28
135	Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 123-128.	2.3	201
136	Effect of neutral endopeptidase inhibition on the natriuresis and renal clearance of atrial natriuretic peptide in perfused rat kidney. <i>Pharmaceutical Research</i> , 1998, 15, 1499-1502.	1.7	1
137	Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. <i>Pharmaceutical Research</i> , 1998, 15, 1609-1613.	1.7	70
138	Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. <i>Pharmaceutical Research</i> , 1998, 15, 734-738.	1.7	26
139	Cellular and molecular mechanisms of renal tubular secretion of organic anions and cations. <i>Clinical and Experimental Nephrology</i> , 1998, 2, 100-108.	0.7	41
140	Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. <i>FEBS Letters</i> , 1998, 438, 321-324.	1.3	124
141	mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. <i>FEBS Letters</i> , 1997, 407, 127-131.	1.3	81
142	Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. <i>Pharmaceutical Research</i> , 1997, 14, 508-511.	1.7	21
143	Kinetic analysis of tetraethylammonium transport in the kidney epithelial cell line, LLC-PK1. <i>Pharmaceutical Research</i> , 1997, 14, 1236-1240.	1.7	18
144	Identification of the histidine residues involved in substrate recognition by a rat H ⁺ /peptide cotransporter, PEPT1. <i>FEBS Letters</i> , 1996, 394, 196-200.	1.3	81

#	ARTICLE	IF	CITATIONS
145	Immuno-Localization of H ⁺ /Peptide Cotransporter in Rat Digestive Tract. <i>Biochemical and Biophysical Research Communications</i> , 1996, 220, 848-852.	1.0	213
146	cDNA Cloning and Functional Expression of a Novel Rat Kidney Organic Cation Transporter, OCT2. <i>Biochemical and Biophysical Research Communications</i> , 1996, 224, 500-507.	1.0	335
147	Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. <i>Pharmaceutical Research</i> , 1996, 13, 1073-1077.	1.7	33
148	Modulation of organic cation transport and lipid fluidity by benzyl alcohol in rat renal brush-border membranes. <i>Pharmaceutical Research</i> , 1996, 13, 1069-1072.	1.7	2
149	Transport characteristics of ceftibuten, a new cephalosporin antibiotic, via the apical H ⁺ /dipeptide cotransport system in human intestinal cell line Caco-2: regulation by cell growth. <i>Pharmaceutical Research</i> , 1995, 12, 1483-1487.	1.7	17
150	Decreased cellular toxicity of neomycin in a clonal cell line isolated from LLC-PK1. <i>Pharmaceutical Research</i> , 1993, 10, 573-576.	1.7	4
151	Analysis of Regulatory Mechanisms for Tubular Secretion of Organic Cations by Cultured Renal Cells. <i>Drug Metabolism and Pharmacokinetics</i> , 1993, 8, 719-722.	0.0	0
152	Decreased transport of p-aminohippurate in renal basolateral membranes isolated from rats with acute renal failure. <i>Pharmaceutical Research</i> , 1989, 06, 954-957.	1.7	9
153	Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1984, 773, 113-124.	1.4	152
154	Carrier-mediated transport of amino-cephalosporins by brush border membrane vesicles isolated from rat kidney cortex. <i>Biochemical Pharmacology</i> , 1983, 32, 621-626.	2.0	42